Recap of Key U.S. Biotechnology and Pharmaceutical Sector Events: October 17
Celgene (NASDAQ: CELG) announced successful phase 1b data of its antisense therapy GED-0301 in the treatment of Crohn's disease (48% remission rate...
205 Views
The Chickens Are Ready to Roost
Several recent developments confirm our thesis that Inflectra's US sales in 2017 will fall far short of management's 2017 forecast. First, Pfizer's...
194 Views
Could Blue-Chip Bristol-Myers Squibb's (NYSE: BMY) Shares Rise More than 40% by Early 2018?
Bristol-Myers Squibb (NYSE: BMY) common stock is trading close to 52-week lows after the failure of pivotal phase 3 trial of Opdivo (anti-PD1...
214 Views
Strike 2 in St Louis: Trump's Town Hall Trap
Before the Battle. Even before this key 2nd presidential debate in St Louis on October 9 (but October 10 Thai time), the press raised many issues....
199 Views
2016 US Elections Scenario Two: Donald Trump Wins
A US election fought under moderately favourable economic conditions, with a Republican electorate divided and openly unhappy with its...
210 Views